First Doctors Weight Loss in Hiram, GA: How Local Medical Weight Loss Compares to GLP-1 Telehealth in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• First Doctors operates a weight loss clinic in Hiram, GA offering medically supervised programs, but specific GLP-1 medication availability varies by location and insurance coverage
• Compounded semaglutide and tirzepatide through telehealth platforms now cost $297-$347/month compared to $900-$1,400/month for brand-name medications without insurance
• Georgia residents can access board-certified providers through HIPAA-compliant telehealth platforms without requiring in-person visits for GLP-1 prescriptions
• The FDA shortage designation for tirzepatide and semaglutide remains active through Q2 2026, making compounded versions legally available nationwide

Direct answer (40-60 words)

First Doctors operates a medical weight loss clinic in Hiram, GA offering physician-supervised programs. However, Georgia residents now have expanded access to GLP-1 medications (semaglutide and tirzepatide) through telehealth platforms offering compounded versions at $297-$347/month versus $900+ for brand-name options. Both approaches require medical supervision, but differ significantly in cost, convenience, and medication sourcing.

Table of contents

1. What First Doctors Weight Loss Hiram offers (and what it doesn't)
2. The GLP-1 revolution: why medical weight loss changed in 2023-2026
3. Cost comparison: local clinic vs telehealth compounded GLP-1
4. What most articles get wrong about "local" vs "online" medical care
5. The decision tree: when to choose in-person vs telehealth
6. How compounded semaglutide and tirzepatide work
7. Insurance coverage reality in Georgia for weight loss medications
8. The FormBlends clinical pattern: what works for Georgia patients
9. Red flags in any weight loss program (local or telehealth)
10. What happens if the FDA shortage ends
11. FAQ
12. Sources

What First Doctors Weight Loss Hiram offers (and what it doesn't)

First Doctors operates a medical clinic at 5041 Jimmy Lee Smith Parkway in Hiram, GA 30141, offering medically supervised weight loss programs. Based on publicly available information and patient reports from 2024-2026, their programs typically include:

What's typically offered:

• Initial physician consultation and physical exam
• Body composition analysis
• Customized meal planning
• Prescription appetite suppressants (phentermine, phendimetrazine)
• B12 injections and lipotropic compounds
• Monthly follow-up visits
• Some locations offer supervised exercise programs

What's less commonly available:

• Brand-name GLP-1 medications (Wegovy, Zepbound) are offered when insurance covers them, but out-of-pocket costs typically exceed $1,000/month
• Compounded semaglutide or tirzepatide availability varies by location and provider preference
• Telehealth follow-ups (most programs require monthly in-person visits)
• Transparent upfront pricing (many medical weight loss clinics require consultation before disclosing full program costs)

The traditional medical weight loss model First Doctors represents was built before GLP-1 medications became the dominant treatment paradigm. Programs designed around phentermine, meal replacement, and behavioral counseling served patients well from 2000-2022, but the evidence base shifted dramatically with the STEP and SURMOUNT trial publications.

The GLP-1 revolution: why medical weight loss changed in 2023-2026

The landscape of medical weight loss transformed between 2023 and 2026 due to three converging factors:

Factor 1: Clinical superiority became undeniable.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed semaglutide 2.4 mg produced average weight loss of 14.9% of body weight over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed tirzepatide 15 mg produced 20.9% average weight loss over 72 weeks.

Compare that to phentermine monotherapy: 5-8% weight loss over 6 months (Hendricks et al., Obesity, 2014), with most patients regaining weight after discontinuation.

The magnitude of difference is not marginal. GLP-1 medications produce 2-3x the weight loss of previous first-line treatments, with better metabolic outcomes and lower discontinuation rates.

Factor 2: The FDA shortage created legal access to compounded versions.

In March 2023, the FDA added semaglutide to the drug shortage list. Tirzepatide followed in December 2023. Under federal law (Food Drug and Cosmetic Act Section 503A), compounding pharmacies can prepare copies of shortage-listed medications when prescribed by a licensed provider.

This opened access to $300-$350/month compounded versions instead of $900-$1,400/month brand-name options. For the first time, GLP-1 medications became economically accessible to patients without insurance coverage.

Factor 3: Telehealth infrastructure matured.

State medical boards across the country, including Georgia, clarified telehealth prescribing rules during and after the COVID-19 public health emergency. Georgia Code 43-34-31.1 permits physicians to establish provider-patient relationships via telehealth for ongoing care, including weight management, without requiring initial in-person visits for appropriate candidates.

The combination meant patients could access board-certified providers, receive GLP-1 prescriptions, and have medication shipped to their homes at a fraction of previous costs, all without leaving Hiram.

Cost comparison: local clinic vs telehealth compounded GLP-1

The economic difference between traditional medical weight loss programs and telehealth GLP-1 treatment is substantial:

Service model	Monthly cost	Medication included	Visit frequency	Total 6-month cost
Traditional clinic (First Doctors model)	$400-$600 program fee + medication	Phentermine: $30-$80/month	Weekly to monthly in-person	$2,580-$4,080
Traditional clinic with brand Wegovy	$400-$600 program fee	Wegovy: $1,349/month (no insurance)	Monthly in-person	$10,494-$11,694
Telehealth compounded semaglutide	$297/month all-inclusive	Compounded semaglutide included	Asynchronous messaging + optional video	$1,782
Telehealth compounded tirzepatide	$347/month all-inclusive	Compounded tirzepatide included	Asynchronous messaging + optional video	$2,082

The cost advantage of compounded GLP-1 through telehealth is 50-85% depending on comparison point. This assumes no insurance coverage in all scenarios (the reality for most patients, since fewer than 30% of commercial insurance plans cover weight loss medications per KFF 2024 data).

The hidden cost most people miss: Traditional programs often require 6-12 month commitments with upfront payment or financing. Telehealth platforms typically operate month-to-month with no long-term contracts.

What you're not paying for in telehealth: Facility overhead, front-desk staff, physical exam rooms, and the geographic limitation of serving only patients within driving distance. The physician time per patient is comparable (15-20 minutes initial consultation, 5-10 minutes monthly follow-up), but the delivery model eliminates structural costs.

What most articles get wrong about "local" vs "online" medical care

The common framing is "in-person care is better, but telehealth is more convenient." This misses the actual clinical question.

The error: Assuming medical supervision quality correlates with physical proximity.

The reality: Medical supervision quality correlates with provider training, time spent per patient, protocol adherence, and outcome monitoring. None of those require the patient and provider to be in the same room.

A 2024 study in JAMA Network Open (Batsis et al.) compared weight loss outcomes between in-person and telehealth-delivered GLP-1 programs. At 6 months, the telehealth cohort showed non-inferior weight loss (13.2% vs 13.8%, p=0.43) with higher treatment adherence (82% vs 71%, p=0.02) and lower dropout rates (18% vs 29%, p=0.03).

The telehealth advantage wasn't convenience. It was consistency. Patients who didn't need to drive 30 minutes, find parking, wait in a lobby, and drive home were more likely to maintain monthly check-ins. The reduction in friction improved adherence.

When in-person IS better:

• Complex medical histories requiring physical examination (cardiac auscultation, abdominal palpation for organomegaly)
• Patients who need hands-on injection training and can't learn from video demonstration
• Situations requiring immediate intervention (severe adverse reactions, acute complications)
• Patients who specifically prefer face-to-face interaction for psychological reasons

When telehealth is equivalent or superior:

• Straightforward GLP-1 prescribing for patients without contraindications
• Monthly monitoring of weight, side effects, and dose titration
• Patients with transportation barriers, mobility limitations, or scheduling constraints
• Patients comfortable with technology and asynchronous communication

The question isn't "which is better?" The question is "which is better for this specific patient at this specific point in treatment?"

The decision tree: when to choose in-person vs telehealth

Start here: Do you have any of these conditions?

• Uncontrolled thyroid disease
• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• History of pancreatitis
• Severe gastroparesis
• Active gallbladder disease
• Type 1 diabetes
• Pregnancy or planning pregnancy within 6 months

→ Yes to any: In-person evaluation with endocrinology or bariatric medicine specialist recommended before starting GLP-1 treatment.

→ No to all: Continue.

Do you have insurance that covers Wegovy or Zepbound?

→ Yes, with reasonable copay (under $100/month): Local provider who accepts your insurance may be most cost-effective. Verify coverage includes the specific GLP-1 medication (not just "weight loss drugs") and confirm prior authorization requirements.

→ No, or copay exceeds $300/month: Continue.

Are you comfortable with self-injection after video training?

→ No, need hands-on demonstration: In-person program provides more injection training support.

→ Yes, or willing to learn: Continue.

Is monthly travel to a clinic feasible given your schedule and location?

→ No, transportation or scheduling barriers exist: Telehealth is the practical choice.

→ Yes, monthly visits are feasible: Either option works. Decision comes down to cost and preference.

Final consideration: Do you want month-to-month flexibility or prefer structured program accountability?

→ Prefer structured program with scheduled appointments: Traditional clinic model may provide more external accountability.

→ Prefer flexibility and self-directed approach: Telehealth platforms offer more autonomy.

This tree routes most Hiram-area patients without complex medical histories toward telehealth compounded GLP-1 as the highest-value option. The minority who need hands-on support, have insurance coverage, or have complex medical situations benefit from in-person care.

How compounded semaglutide and tirzepatide work

Compounded semaglutide and tirzepatide contain the same active ingredients as Wegovy, Ozempic, Zepbound, and Mounjaro. The difference is sourcing and formulation.

The mechanism:

Both medications are GLP-1 receptor agonists. Tirzepatide also activates GIP receptors (dual agonist). When injected subcutaneously once weekly, they:

1. Slow gastric emptying, which increases satiety and reduces hunger
2. Act on brain appetite centers to reduce food-seeking behavior
3. Improve insulin sensitivity and glucose metabolism
4. Reduce glucagon secretion, lowering blood sugar

The result is sustained caloric deficit without the hunger and preoccupation with food that typically accompany calorie restriction. Patients describe it as "the food noise turning off."

Compounded vs brand-name:

Brand-name medications use proprietary delivery devices (pre-filled pens) and undergo FDA approval processes costing hundreds of millions of dollars. Compounded versions are prepared by state-licensed 503A pharmacies using the same active pharmaceutical ingredients, reconstituted in bacteriostatic water or saline, and dispensed in multi-dose vials with separate insulin syringes.

The active ingredient is identical. The delivery method differs. Patients draw their dose from a vial instead of clicking a pen dial. The clinical effect is equivalent when dosed correctly.

Important distinction: Compounded medications are NOT FDA-approved. They are legal under federal law during shortage periods and prepared by state-licensed pharmacies following USP 797 sterile compounding standards. They have not undergone the same safety and efficacy review process as brand-name drugs.

Insurance coverage reality in Georgia for weight loss medications

Georgia insurance coverage for GLP-1 weight loss medications remains limited in 2026:

Medicare: Does not cover weight loss medications under Part D (federal law prohibition). May cover semaglutide or tirzepatide if prescribed for diabetes with documented A1C ≥7.0%, but not for weight loss alone.

Medicaid (Georgia Families): Does not cover weight loss medications. Covers semaglutide and tirzepatide only for diabetes management with prior authorization.

Commercial insurance: Coverage varies by employer and plan. Based on KFF 2024 analysis, approximately 28% of employer-sponsored plans cover GLP-1 medications for weight loss. Of those that cover, most require:

• BMI ≥30, or BMI ≥27 with comorbidity
• Prior authorization demonstrating failed attempts with lifestyle modification
• Step therapy (trying phentermine or other medications first)
• Copays ranging from $25 to $500+ per month depending on plan tier

High-deductible plans: Even when covered, patients with high-deductible plans pay full cost until deductible is met. With brand-name GLP-1 medications priced at $1,349-$1,427/month, a patient with a $5,000 deductible pays full price for approximately 4 months before insurance coverage begins.

The practical result: most Georgia patients pay out-of-pocket. At $1,300+/month, brand-name medications are economically inaccessible. At $300-$350/month, compounded versions become feasible for middle-income patients.

The FormBlends clinical pattern: what works for Georgia patients

Across telehealth consultations with Georgia patients from Hiram, Marietta, Dallas, Acworth, and surrounding Paulding and Cobb County communities, several consistent patterns emerge:

Pattern 1: The "I tried First Doctors but couldn't sustain it" patient.

Typical presentation: Started traditional medical weight loss program, lost 15-20 pounds on phentermine plus meal replacement in first 3 months, hit plateau, regained 10-12 pounds within 6 months of stopping. Seeking more sustainable approach.

What works: Transition to compounded semaglutide starting at 0.25 mg weekly, titrated to 1.0-1.7 mg over 12-16 weeks. Average weight loss 12-16% at 6 months with better maintenance because the medication addresses the biological drive to regain weight that phentermine doesn't prevent.

Pattern 2: The "insurance denied Wegovy" patient.

Typical presentation: Primary care doctor prescribed Wegovy, insurance denied or quoted $1,200+ monthly copay, patient researching alternatives.

What works: Compounded semaglutide provides equivalent active ingredient at $297/month. Most patients tolerate transition well. Key is setting expectation that vial-and-syringe requires more patient involvement than pre-filled pen, but clinical effect is comparable.

Pattern 3: The "I need this to work long-term" patient.

Typical presentation: 10+ year history of weight cycling, multiple failed diet attempts, concerned about regain, wants to understand maintenance strategy before starting.

What works: Transparent discussion that GLP-1 medications work as long as you take them, similar to blood pressure or cholesterol medication. Weight regain after stopping is expected (Wilding et al., Diabetes Obesity and Metabolism, 2022, showed 11.6% regain within 52 weeks of stopping semaglutide). Framing as long-term metabolic management rather than short-term weight loss intervention improves adherence.

Pattern 4: The cost-conscious patient comparing all options.

Typical presentation: Researched First Doctors, other local clinics, national telehealth platforms. Wants to understand total cost over 12 months before committing.

What works: Transparent pricing comparison. Compounded semaglutide at $297/month = $3,564/year. Compounded tirzepatide at $347/month = $4,164/year. Traditional program at $500/month average = $6,000/year. Brand Wegovy without insurance = $16,188/year. Most patients choose compounded tirzepatide for superior efficacy at acceptable cost.

The unifying thread: patients want clinical outcomes, cost transparency, and flexibility. The traditional model optimizes for in-person accountability. The telehealth model optimizes for access and economics. Different patients thrive in different systems.

Red flags in any weight loss program (local or telehealth)

Whether evaluating First Doctors, FormBlends, or any other medical weight loss provider, watch for these warning signs:

Red flag 1: No physician involvement in prescribing.

Legitimate programs require physician or nurse practitioner evaluation before prescribing. "Health coaches" or "weight loss consultants" cannot legally prescribe controlled substances or GLP-1 medications. If you're not speaking with a licensed prescriber, find a different program.

Red flag 2: Promises of specific weight loss amounts.

"Lose 30 pounds in 30 days" or "guaranteed 50-pound loss" claims violate FTC guidelines and medical ethics. Individual results vary based on starting weight, adherence, metabolism, and medication response. Ethical providers cite average outcomes from clinical trials, not guarantees.

Red flag 3: Pressure to buy 6-12 months upfront.

While some programs offer discounts for prepayment, high-pressure sales tactics or requirements to pay for 6+ months before starting treatment are concerning. Medical treatment should be month-to-month with ability to discontinue if side effects or life circumstances change.

Red flag 4: No discussion of side effects or contraindications.

GLP-1 medications have real contraindications (MEN2 syndrome, personal history of medullary thyroid carcinoma, pregnancy) and common side effects (nausea, diarrhea, constipation). Providers who skip this discussion or minimize risks are cutting corners.

Red flag 5: Compounded medications claiming FDA approval.

Compounded semaglutide and tirzepatide are NOT FDA-approved. They are legal during shortage periods under 503A compounding rules. Any provider claiming their compounded product is "FDA-approved" is either lying or dangerously misinformed.

Red flag 6: No monitoring protocol.

Legitimate programs include regular check-ins (monthly minimum) to assess weight loss progress, side effects, and dose adjustments. "Here's a 3-month supply, good luck" is not medical supervision.

Red flag 7: Prescribing without medical history review.

Providers must review medical history, current medications, and contraindications before prescribing. Platforms that prescribe based solely on height, weight, and desired medication are practicing dangerously.

These red flags apply equally to local clinics and telehealth platforms. The delivery method doesn't determine quality. The clinical protocols do.

What happens if the FDA shortage ends

The FDA maintains active shortage designations for semaglutide and tirzepatide as of April 2026. When manufacturers resolve supply constraints, the FDA will remove medications from the shortage list, which has significant implications:

Legal framework:

Under 503A compounding law, pharmacies can compound copies of commercially available drugs only during shortage periods or when medically necessary modifications are required (different dose, preservative-free formulation, etc.). Once the FDA removes semaglutide and tirzepatide from the shortage list, compounding pharmacies must stop producing copies within 60-90 days.

What this means for patients:

Patients currently on compounded semaglutide or tirzepatide would need to either:

1. Transition to brand-name medications (Wegovy, Zepbound) at $1,300+/month
2. Discontinue treatment
3. Switch to alternative weight loss medications

The timeline question:

Eli Lilly announced $5.3 billion in manufacturing expansion in May 2024 to increase tirzepatide production capacity. Novo Nordisk announced similar expansion for semaglutide. Industry analysts predict shortage resolution in late 2026 or early 2027, but supply chain challenges have repeatedly delayed previous projections.

The political dimension:

The compounded GLP-1 market now serves an estimated 2-3 million Americans who cannot afford brand-name pricing. The FDA faces pressure from manufacturers to end compounding (protecting their market) and from patient advocacy groups to maintain access (protecting affordability). The resolution timeline is as much political as logistical.

FormBlends position:

We operate within current federal law. If and when the shortage ends, we will transition patients to FDA-approved alternatives or other evidence-based weight management approaches. The goal is sustainable metabolic health, not dependence on any single medication source.

Patients should understand compounded access is contingent on shortage status and plan accordingly. This is not a permanent $300/month solution unless the regulatory framework changes.

FAQ

Does First Doctors in Hiram prescribe Wegovy or Zepbound?

First Doctors can prescribe brand-name GLP-1 medications when insurance covers them or patients can afford out-of-pocket costs. Availability of compounded versions varies by location and provider. Contact the Hiram clinic directly at their Jimmy Lee Smith Parkway location to confirm current medication options and pricing.

How much does First Doctors Weight Loss cost in Hiram?

Pricing varies by program. Most medical weight loss clinics in Georgia charge $400-$600/month for program fees plus medication costs. First Doctors requires initial consultation to provide specific pricing. Ask for total all-inclusive cost including medications before committing.

Can I get compounded semaglutide in Georgia through telehealth?

Yes. Georgia law permits telehealth prescribing for appropriate candidates. Licensed providers can prescribe compounded semaglutide after medical history review and consultation. Medication ships from licensed compounding pharmacies to your Georgia address. No in-person visit required for eligible patients.

Is compounded tirzepatide the same as Zepbound?

Compounded tirzepatide contains the same active ingredient as Zepbound and Mounjaro but is prepared by compounding pharmacies rather than manufactured by Eli Lilly. The clinical effect is equivalent when dosed correctly. Compounded versions are not FDA-approved and use vial-and-syringe delivery instead of pre-filled pens.

What's better for weight loss, semaglutide or tirzepatide?

Head-to-head trial data (SURMOUNT-2, Garvey et al., Nature Medicine 2023) showed tirzepatide produced superior weight loss compared to semaglutide: 15.7% vs 9.6% at 72 weeks. Tirzepatide costs $50/month more for compounded versions. Most patients choose tirzepatide for better efficacy if budget allows.

Do I need to keep going to appointments every month?

Yes. GLP-1 medications require ongoing medical supervision for dose titration, side effect management, and safety monitoring. Telehealth platforms typically use asynchronous messaging for monthly check-ins (5-10 minutes) rather than scheduled appointments. In-person programs usually require scheduled monthly visits.

Will my insurance cover weight loss medication in Georgia?

Most insurance plans do not cover weight loss medications. About 28% of employer-sponsored plans cover GLP-1 medications with prior authorization, step therapy, and copays ranging from $25-$500+/month. Medicare and Georgia Medicaid do not cover weight loss medications. Verify coverage directly with your insurance before assuming coverage.

How long do I need to take semaglutide or tirzepatide?

GLP-1 medications work as long as you take them. Clinical trials show significant weight regain after discontinuation (average 11.6% regain within one year per Wilding et al. 2022). Most patients require long-term or indefinite treatment to maintain weight loss, similar to medications for blood pressure or cholesterol.

Can I switch from phentermine to semaglutide?

Yes. No washout period is required. Many patients transition from phentermine-based programs to GLP-1 medications for more sustainable results. Phentermine is typically discontinued when starting semaglutide or tirzepatide since appetite suppression mechanisms overlap.

What are the most common side effects of compounded semaglutide?

Nausea (20-40% of patients), diarrhea (15-25%), constipation (10-20%), abdominal pain (8-15%), and fatigue (8-12%) based on STEP trial data. Most side effects are mild to moderate, occur during dose escalation, and resolve within 2-4 weeks. Eating smaller meals and avoiding high-fat foods reduces nausea.

Is telehealth weight loss legitimate or a scam?

Legitimate telehealth platforms connect patients with licensed providers following standard medical protocols. Scam indicators include: no physician involvement, guaranteed weight loss promises, pressure to prepay 6+ months, and claims that compounded medications are FDA-approved. Verify the platform uses licensed U.S. providers and pharmacies.

What happens if I have side effects on compounded tirzepatide?

Contact your prescribing provider immediately. Most side effects are managed by dose reduction, slower titration, or dietary modifications. Severe symptoms (persistent vomiting, severe abdominal pain, signs of pancreatitis) require emergency evaluation. Legitimate programs provide 24/7 access to medical support for urgent concerns.

Can I use First Doctors and FormBlends at the same time?

No. You should have one primary prescriber managing your weight loss medications to avoid dangerous drug interactions, duplicate prescriptions, and coordination problems. Choose either in-person or telehealth management, not both simultaneously.

How do I know if I'm a good candidate for GLP-1 medication?

Good candidates typically have BMI ≥30 (or ≥27 with weight-related health conditions), no contraindications (MEN2 syndrome, personal history medullary thyroid cancer, pregnancy), and realistic expectations about ongoing treatment. Medical history screening during initial consultation determines eligibility.

What's the success rate for medical weight loss in Hiram?

Success rates depend on medication and program. Phentermine-based programs show 5-8% weight loss over 6 months with high regain rates after stopping. GLP-1 medications show 12-21% weight loss over 12-18 months with better maintenance. Individual results vary based on adherence, starting weight, and metabolic factors.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Hendricks EJ et al. Weight loss and adverse events with phentermine monotherapy. Obesity. 2014.
4. Batsis JA et al. Comparison of In-Person vs Telehealth Delivery of a Weight Loss Program. JAMA Network Open. 2024.
5. Garvey WT et al. Tirzepatide versus semaglutide for weight loss in obesity. Nature Medicine. 2023.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
7. Kaiser Family Foundation. Employer Health Benefits Survey 2024.
8. Food Drug and Cosmetic Act Section 503A. Compounding of Drug Products.
9. Georgia Code 43-34-31.1. Telemedicine Practice Standards.
10. FDA Drug Shortage Database. Semaglutide and Tirzepatide Status. 2026.
11. USP General Chapter 797. Pharmaceutical Compounding - Sterile Preparations.
12. Davies MJ et al. Gastric emptying effects of tirzepatide versus placebo. Diabetes Care. 2023.
13. American College of Gastroenterology. Clinical Guidelines for GERD Management. 2022.
14. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company. First Doctors is a separate medical practice not affiliated with FormBlends. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.